XBiotech Inc. (XBIT) stock
XBITNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.96+0.00 (0.00%)
Close on Nov 13, 2026Market cap $59.76MP/E –Yield –
XBiotech r&d expenses
Research and development expenses are spending on new products and technology.
XBiotech's R&D Expenses for the twelve months ending Sep 30, 2026 was $40.52M, up 35.7% year over year. For fiscal 2025 it was $47.39M, up 25.5% from the year before. Over ten years it grew 4.2% a year on average. The highest annual figure on record is $47.39M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.39M | +25.5% |
| FY2024 | Dec 31, 2024 | $37.76M | +14.9% |
| FY2023 | Dec 31, 2023 | $32.85M | +4.1% |
| FY2022 | Dec 31, 2022 | $31.54M | +11.6% |
| FY2021 | Dec 31, 2021 | $28.27M | +196.7% |
| FY2020 | Dec 31, 2020 | $9.53M | -60.5% |
| FY2019 | Dec 31, 2019 | $24.09M | +53.2% |
| FY2018 | Dec 31, 2018 | $15.73M | -40.5% |
| FY2017 | Dec 31, 2017 | $26.42M | -37.8% |
| FY2016 | Dec 31, 2016 | $42.49M | +35.7% |
| FY2015 | Dec 31, 2015 | $31.31M | +118.5% |
| FY2014 | Dec 31, 2014 | $14.33M | +80.6% |
| FY2013 | Dec 31, 2013 | $7.94M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.66M | -8.3% |
| Q2 FY2026 | Jun 30, 2026 | $5.30M | -0.7% |
| Q1 FY2026 | Mar 31, 2026 | $5.21M | -55.2% |
| Q4 FY2025 | Dec 31, 2025 | $25.36M | +224.2% |
| Q3 FY2025 | Sep 30, 2025 | $5.08M | -28.7% |
| Q2 FY2025 | Jun 30, 2025 | $5.34M | -58.9% |
| Q1 FY2025 | Mar 31, 2025 | $11.62M | +18.3% |
| Q4 FY2024 | Dec 31, 2024 | $7.82M | +0.2% |
| Q3 FY2024 | Sep 30, 2024 | $7.13M | -5.6% |
| Q2 FY2024 | Jun 30, 2024 | $12.98M | +15.2% |
| Q1 FY2024 | Mar 31, 2024 | $9.83M | +57.7% |
| Q4 FY2023 | Dec 31, 2023 | $7.80M | +6.7% |
| Q3 FY2023 | Sep 30, 2023 | $7.55M | +7.6% |
| Q2 FY2023 | Jun 30, 2023 | $11.27M | +8.4% |
| Q1 FY2023 | Mar 31, 2023 | $6.23M | -8.6% |
| Q4 FY2022 | Dec 31, 2022 | $7.32M | -16.7% |
| Q3 FY2022 | Sep 30, 2022 | $7.01M | +25.3% |
| Q2 FY2022 | Jun 30, 2022 | $10.39M | +12.3% |
| Q1 FY2022 | Mar 31, 2022 | $6.82M | +47.1% |
| Q4 FY2021 | Dec 31, 2021 | $8.78M | +153.7% |
| Q3 FY2021 | Sep 30, 2021 | $5.60M | +138.7% |
| Q2 FY2021 | Jun 30, 2021 | $9.25M | +260.8% |
| Q1 FY2021 | Mar 31, 2021 | $4.63M | +301.2% |
| Q4 FY2020 | Dec 31, 2020 | $3.46M | -66.5% |
| Q3 FY2020 | Sep 30, 2020 | $2.35M | -48.2% |
| Q2 FY2020 | Jun 30, 2020 | $2.57M | -45.3% |
| Q1 FY2020 | Mar 31, 2020 | $1.16M | -74.5% |
| Q4 FY2019 | Dec 31, 2019 | $10.34M | +113.4% |
| Q3 FY2019 | Sep 30, 2019 | $4.53M | +15.1% |
| Q2 FY2019 | Jun 30, 2019 | $4.69M | +18.8% |
| Q1 FY2019 | Mar 31, 2019 | $4.53M | +51.3% |
| Q4 FY2018 | Dec 31, 2018 | $4.84M | -18.0% |
| Q3 FY2018 | Sep 30, 2018 | $3.94M | -20.1% |
| Q2 FY2018 | Jun 30, 2018 | $3.95M | -46.6% |
| Q1 FY2018 | Mar 31, 2018 | $2.99M | -63.4% |
| Q4 FY2017 | Dec 31, 2017 | $5.91M | -56.8% |
| Q3 FY2017 | Sep 30, 2017 | $4.93M | – |
| Q2 FY2017 | Jun 30, 2017 | $7.40M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.19M | – |
| Q4 FY2016 | Dec 31, 2016 | $13.69M | – |
See a number that looks wrong?